What is the appropriate management of non-functioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?

Benjamin G. Challis (Lead / Corresponding author), Ruth T. Casey, Ashley Grossman, John Newell-Price, Paul Newey, Rajesh V. Thakker

Research output: Contribution to journalArticle

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an inherited tumour syndrome characterised by a predisposition to the development of endocrine tumours of the parathyroid glands, pituitary and pancreas: 30-80% of patients with MEN1 develop pancreatic neuroendocrine tumours (pNETs), with metastatic tumours and/or their sequelae contributing to increased morbidity and early mortality. The optimal management of non-functioning (NF) pNETs in MEN1 remains controversial. Whilst pancreatic resection is widely recommended for tumours >2cm, for smaller tumours (≤2cm) a well-established consensus guiding the indications for surgical intervention does not exist. Although total pancreatectomy may be curative for some patients, both short- and long-term complications makes this an unsatisfactory option for many patients. For small (<2cm) MEN1 NF-pNETs, some clinicians advocate surveillance based largely on retrospective data that suggests 50-80% of these lesions are stable over time, and infrequently exhibit accelerated growth rates. It is increasingly recognised, however, that NF-pNETs exhibit unpredictable malignant behaviour that is not determined by tumour size alone, thereby prompting other clinicians to advocate surgery for all MEN1 NF-pNETs, irrespective of size. Such uncertainty poses clinical management challenges with regards to the timing and extent of surgery, which is further hindered by the inability to stratify patients based on predicted tumour behaviour. It is therefore critical that future MEN1 research initiatives include: 1) the discovery of biomarkers that better predict tumour behaviour; 2) the evaluation of medical therapies that may delay, or even prevent, the need for pancreatic surgery; and, ultimately, 3) improvement in the quality of life for individuals with MEN1. Here, based on the published literature, we address the Clinical Question, 'What is the management of NF-pNETs disclosed on screening in adult patients with MEN1?'.

Original languageEnglish
JournalClinical Endocrinology
DOIs
Publication statusE-pub ahead of print - 10 Sep 2019

Fingerprint

Multiple Endocrine Neoplasia Type 1
Neuroendocrine Tumors
Neoplasms
Pancreatectomy
Parathyroid Glands
Uncertainty
Pancreas
Biomarkers
Quality of Life
Morbidity
Mortality

Cite this

@article{6281639a581f44069d6f232b634a7530,
title = "What is the appropriate management of non-functioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?",
abstract = "Multiple endocrine neoplasia type 1 (MEN1) is an inherited tumour syndrome characterised by a predisposition to the development of endocrine tumours of the parathyroid glands, pituitary and pancreas: 30-80{\%} of patients with MEN1 develop pancreatic neuroendocrine tumours (pNETs), with metastatic tumours and/or their sequelae contributing to increased morbidity and early mortality. The optimal management of non-functioning (NF) pNETs in MEN1 remains controversial. Whilst pancreatic resection is widely recommended for tumours >2cm, for smaller tumours (≤2cm) a well-established consensus guiding the indications for surgical intervention does not exist. Although total pancreatectomy may be curative for some patients, both short- and long-term complications makes this an unsatisfactory option for many patients. For small (<2cm) MEN1 NF-pNETs, some clinicians advocate surveillance based largely on retrospective data that suggests 50-80{\%} of these lesions are stable over time, and infrequently exhibit accelerated growth rates. It is increasingly recognised, however, that NF-pNETs exhibit unpredictable malignant behaviour that is not determined by tumour size alone, thereby prompting other clinicians to advocate surgery for all MEN1 NF-pNETs, irrespective of size. Such uncertainty poses clinical management challenges with regards to the timing and extent of surgery, which is further hindered by the inability to stratify patients based on predicted tumour behaviour. It is therefore critical that future MEN1 research initiatives include: 1) the discovery of biomarkers that better predict tumour behaviour; 2) the evaluation of medical therapies that may delay, or even prevent, the need for pancreatic surgery; and, ultimately, 3) improvement in the quality of life for individuals with MEN1. Here, based on the published literature, we address the Clinical Question, 'What is the management of NF-pNETs disclosed on screening in adult patients with MEN1?'.",
author = "Challis, {Benjamin G.} and Casey, {Ruth T.} and Ashley Grossman and John Newell-Price and Paul Newey and Thakker, {Rajesh V.}",
note = "{\circledC} 2019 John Wiley & Sons Ltd.",
year = "2019",
month = "9",
day = "10",
doi = "10.1111/cen.14094",
language = "English",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley",

}

What is the appropriate management of non-functioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1? / Challis, Benjamin G. (Lead / Corresponding author); Casey, Ruth T.; Grossman, Ashley; Newell-Price, John; Newey, Paul; Thakker, Rajesh V.

In: Clinical Endocrinology, 10.09.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - What is the appropriate management of non-functioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?

AU - Challis, Benjamin G.

AU - Casey, Ruth T.

AU - Grossman, Ashley

AU - Newell-Price, John

AU - Newey, Paul

AU - Thakker, Rajesh V.

N1 - © 2019 John Wiley & Sons Ltd.

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Multiple endocrine neoplasia type 1 (MEN1) is an inherited tumour syndrome characterised by a predisposition to the development of endocrine tumours of the parathyroid glands, pituitary and pancreas: 30-80% of patients with MEN1 develop pancreatic neuroendocrine tumours (pNETs), with metastatic tumours and/or their sequelae contributing to increased morbidity and early mortality. The optimal management of non-functioning (NF) pNETs in MEN1 remains controversial. Whilst pancreatic resection is widely recommended for tumours >2cm, for smaller tumours (≤2cm) a well-established consensus guiding the indications for surgical intervention does not exist. Although total pancreatectomy may be curative for some patients, both short- and long-term complications makes this an unsatisfactory option for many patients. For small (<2cm) MEN1 NF-pNETs, some clinicians advocate surveillance based largely on retrospective data that suggests 50-80% of these lesions are stable over time, and infrequently exhibit accelerated growth rates. It is increasingly recognised, however, that NF-pNETs exhibit unpredictable malignant behaviour that is not determined by tumour size alone, thereby prompting other clinicians to advocate surgery for all MEN1 NF-pNETs, irrespective of size. Such uncertainty poses clinical management challenges with regards to the timing and extent of surgery, which is further hindered by the inability to stratify patients based on predicted tumour behaviour. It is therefore critical that future MEN1 research initiatives include: 1) the discovery of biomarkers that better predict tumour behaviour; 2) the evaluation of medical therapies that may delay, or even prevent, the need for pancreatic surgery; and, ultimately, 3) improvement in the quality of life for individuals with MEN1. Here, based on the published literature, we address the Clinical Question, 'What is the management of NF-pNETs disclosed on screening in adult patients with MEN1?'.

AB - Multiple endocrine neoplasia type 1 (MEN1) is an inherited tumour syndrome characterised by a predisposition to the development of endocrine tumours of the parathyroid glands, pituitary and pancreas: 30-80% of patients with MEN1 develop pancreatic neuroendocrine tumours (pNETs), with metastatic tumours and/or their sequelae contributing to increased morbidity and early mortality. The optimal management of non-functioning (NF) pNETs in MEN1 remains controversial. Whilst pancreatic resection is widely recommended for tumours >2cm, for smaller tumours (≤2cm) a well-established consensus guiding the indications for surgical intervention does not exist. Although total pancreatectomy may be curative for some patients, both short- and long-term complications makes this an unsatisfactory option for many patients. For small (<2cm) MEN1 NF-pNETs, some clinicians advocate surveillance based largely on retrospective data that suggests 50-80% of these lesions are stable over time, and infrequently exhibit accelerated growth rates. It is increasingly recognised, however, that NF-pNETs exhibit unpredictable malignant behaviour that is not determined by tumour size alone, thereby prompting other clinicians to advocate surgery for all MEN1 NF-pNETs, irrespective of size. Such uncertainty poses clinical management challenges with regards to the timing and extent of surgery, which is further hindered by the inability to stratify patients based on predicted tumour behaviour. It is therefore critical that future MEN1 research initiatives include: 1) the discovery of biomarkers that better predict tumour behaviour; 2) the evaluation of medical therapies that may delay, or even prevent, the need for pancreatic surgery; and, ultimately, 3) improvement in the quality of life for individuals with MEN1. Here, based on the published literature, we address the Clinical Question, 'What is the management of NF-pNETs disclosed on screening in adult patients with MEN1?'.

U2 - 10.1111/cen.14094

DO - 10.1111/cen.14094

M3 - Article

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

ER -